Effects of a 12-Week Solid Beverage Intervention on Suboptimal Health Status
NCT07884643, Not applicable, Recruiting, ChinaNorm
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Effects of a 12-Week Solid Beverage Intervention on Suboptimal Health Status | ClinicalTrials.gov |
| NCT number | NCT07884643 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 70 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | ChinaNorm | ClinicalTrials.gov |
| Conditions | Metabolic Disorder, Sub-health Status | ClinicalTrials.gov |
| Interventions | Meta Solid Beverage A, Meta Solid Beverage B | ClinicalTrials.gov |
| First posted | 2026-10-20 | ClinicalTrials.gov |
| Last updated | 2026-10-20 | ClinicalTrials.gov |
Registered outcomes 32
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in Metabolic Syndrome Risk Index (MetS) | Baseline and 12 weeks after intervention | Change from baseline in Metabolic Syndrome Risk Index (MetS). This composite index integrates body composition, glucose metabolism and lipid metabolism indicators to assess the overall metabolic risk and systemic sub-health improvement of subjects. | ClinicalTrials.gov |
| Secondary | Change in waist circumference | Baseline, 4, 8 and 12 weeks after intervention | Change from baseline in waist circumference, to assess central obesity improvement. | ClinicalTrials.gov |
| Secondary | Change in basal metabolic rate calculated by Cunningham formula | Baseline, 4, 8 and 12 weeks after intervention | Change from baseline in basal metabolic rate calculated by Cunningham formula, derived from body fat percentage, to assess changes in resting energy consumption. | ClinicalTrials.gov |
| Secondary | Change in fasting blood glucose | Baseline and 12 weeks after intervention | Change from baseline in fasting blood glucose, to evaluate glucose metabolism status. | ClinicalTrials.gov |
| Secondary | Change in HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) | Baseline and 12 weeks after intervention | Change from baseline in HOMA-IR (Homeostatic Model Assessment of Insulin Resistance). HOMA-IR is a single derived value calculated using fasting blood glucose and fasting insulin, to assess insulin sensitivity. | ClinicalTrials.gov |
| Secondary | Change in systolic blood pressure and diastolic blood pressure | Baseline, 4, 8 and 12 weeks after intervention | Change from baseline in systolic blood pressure and diastolic blood pressure, to evaluate vascular function, which is not included in Metabolic Syndrome Risk Index aggregation. | ClinicalTrials.gov |
| Secondary | Change in palm skin surface temperature | Baseline, 4, 8 and 12 weeks after intervention | Change from baseline in palm skin surface temperature, for objective evaluation of peripheral microcirculation improvement, associated with relief of cold extremity symptoms. | ClinicalTrials.gov |
| Secondary | Change in SF-36 health survey summary score | Baseline, 4, 8 and 12 weeks after intervention | Change from baseline in the 36-Item Short Form Health Survey (SF-36). SF-36 yields two summary scores: Physical Component Summary (PCS) and Mental Component Summary (MCS). Each summary score ranges from 0 to 100, higher scores indicate better health-related quality of life, to assess health-related quality of life improvement. | ClinicalTrials.gov |
| Secondary | Change in Bristol stool form scale score | Baseline, 4, 8 and 12 weeks after intervention | Change from baseline in Bristol Stool Form Scale (BSFS) score. The unabbreviated scale name is Bristol Stool Form Scale; individual raw scores range from 1 to 7. Higher raw BSFS scores represent looser stool consistency. | ClinicalTrials.gov |
| Secondary | Subjective product evaluation questionnaire score | 4, 8 and 12 weeks after intervention | Total score from the Subjective Product Evaluation Questionnaire, a study-specific questionnaire containing 12 items to assess participants' subjective perception and satisfaction with the investigational product. Each item is rated from 1 (strongly disagree) to 5 (strongly agree). The total score ranges from 12 to 60; higher total scores indicate greater perceived improvement and higher satisfaction with the investigational product. | ClinicalTrials.gov |
| Secondary | Change in hip circumference | Baseline, 4, 8 and 12 weeks after intervention | Change from baseline in hip circumference, to assess central obesity improvement. | ClinicalTrials.gov |
| Secondary | Change in waist-to-height ratio | Baseline, 4, 8 and 12 weeks after intervention | Change from baseline in waist-to-height ratio, to assess central obesity improvement. | ClinicalTrials.gov |
| Secondary | Change in waist-to-hip ratio | Baseline, 4, 8 and 12 weeks after intervention | Change from baseline in waist-to-hip ratio, to assess central obesity improvement. | ClinicalTrials.gov |
| Secondary | Change in body fat percentage | Baseline, 4, 8 and 12 weeks after intervention | Change from baseline in body fat percentage, to assess body fat improvement. | ClinicalTrials.gov |
| Secondary | Change in body mass index (BMI) | Baseline, 4, 8 and 12 weeks after intervention | Change from baseline in body mass index (BMI), to assess body fat improvement. | ClinicalTrials.gov |
| Secondary | Change in basal metabolic rate calculated by Nelson formula | Baseline, 4, 8 and 12 weeks after intervention | Change from baseline in basal metabolic rate calculated by Nelson formula, derived from body fat percentage, to assess changes in resting energy consumption. | ClinicalTrials.gov |
| Secondary | Change in fasting insulin | Baseline and 12 weeks after intervention | Change from baseline in fasting insulin, to evaluate glucose metabolism status. | ClinicalTrials.gov |
| Secondary | Change in triglyceride | Baseline and 12 weeks after intervention | Change from baseline in triglyceride, to evaluate lipid metabolism status. | ClinicalTrials.gov |
| Secondary | Change in total cholesterol | Baseline and 12 weeks after intervention | Change from baseline in total cholesterol, to evaluate lipid metabolism status. | ClinicalTrials.gov |
| Secondary | Change in low-density lipoprotein cholesterol (LDL-C) | Baseline and 12 weeks after intervention | Change from baseline in low-density lipoprotein cholesterol (LDL-C), to evaluate lipid metabolism status. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| 1-Back Task | Other outcome | ConductCognition |
| 2-Back Task | Other outcome | ConductCognition |
| Stroop Color-Word Test | Other outcome | ConductCognition |
| Symbol Coding | Other outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)